First-line treatment

First-line treatment

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses What is the role for PD-L1 testing after first line treatment for advanced NSCLC in initial diagnosis today.
Cancer Journey:
Cancer Type:
Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC).
Cancer Journey:
Cancer Type:
,
,
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Type:
For our 17th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss first line therapy for NSCLC patients that have anaplastic lymphoma kinase (ALK) positive.
Cancer Journey:
Cancer Type:
Disease Learning:
For our 5th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the most appropriate treatment for elderly patients with advanced NSCLC, and whether age alters the recommendations.
Cancer Journey:
Cancer Type:

Articles

Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line...
Cancer Journey:
Cancer Type:
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of...
Cancer Journey:
Cancer Type:
Fast forward 1.5 years, and we now have the early results of LUX-Lung-7, and they show that these EGFR TKIs are not completely interchangeable...
Cancer Journey:
Cancer Type:
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Cancer Journey:
Cancer Type:
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Cancer Journey:
Cancer Type:

Community Forum

No Result Found